Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD + Acute Myeloid Leukemia
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Bing Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Anti-Infective Drug Development (No. 2015DQ780357), Sunshine Lake Pharma Company, Ltd., Dongguan 523871, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: State Key Laboratory of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Key Research Development Program of Dongguan.
Abstract (Originalsprache)
Internal tandem duplication (ITD) mutations of FLT3 (FLT3-ITD) are a promising target for patients with acute myeloid leukemia (AML), given that they have been identified in the majority of AML patients and are associated with poor prognosis. Here, a series of biphenylacetylene derivatives was developed as selective FLT3-ITD inhibitors. Representative compound 9e exhibited excellent potency against FLT3-ITD kinase, with an IC50 value of 15.1 nM, and potently suppressed the proliferation of MV-4-11 and MOLM-13 AML cells harboring FLT3-ITD, with IC50 values of 1.5 and 1.4 nM, respectively. Moreover, compound 9e displayed favorable drug-like properties and significantly suppressed tumor growth in MV-4-11 (1.5 mg/kg, qd, tumor growth inhibition (TGI) = 193.5%) and MOLM-13 (4.5 mg/kg, qd, TGI = 94%) xenograft tumor models in mice without significant weight loss. Compound 9e (named Clifutinib) is currently being evaluated in a phase III clinical trial (NCT05586074) for the treatment of relapsed/refractory FLT3-ITD-positive AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Anti-Infective Drug Development (No. 2015DQ780357), Sunshine Lake Pharma Company, Ltd., Dongguan 523871, China.
- MOE International Joint Laboratory for Synthetic Biology and Medicines, School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.
- Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Förderung
- State Key Laboratory of Anti-Infective Drug Development
- Sunshine Lake Pharma Co., Ltd.
- Key Research Development Program of Dongguan
Zitieren
APA
Liu, B., Kang, N., Yang, F., Zhang, W., Yan, X., Wang, H., Bai, S., Cheng, C. C., Xu, J., Hu, W., & Zhang, Y. (2025). Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD + Acute Myeloid Leukemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03023
Vancouver
Liu B, Kang N, Yang F, Zhang W, Yan X, Wang H, et al. Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD + Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03023
BibTeX
@article{Liu2025,
author = {Liu, Bing and Kang, Ning and Yang, Fang and Zhang, WeiHong and Yan, XingGuo and Wang, Heng and Bai, Shun and Cheng, Cliff C and Xu, Juan and Hu, WenHao and Zhang, YingJun},
title = {Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD + Acute Myeloid Leukemia},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03023}
}
EUVIMED